Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Quemliclustat (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arcus Biosciences
- 18 Mar 2022 Results of pharmacokinetic/pharmacodynamic model of quemliclustat by using data from two studies (AB680CSP0001 and ARC-8) presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 14 Aug 2019 Planned End Date changed from 26 Aug 2019 to 18 Aug 2019.